Member Info for peterobert

9.10-9.49p

Starting to make its move

Ondine Biomedical Inc - Vancouver-based life sciences company - Appoints Joseph Errico as chief financial officer, though doesn't provide start date. Says Errico has successfully founded, sold, or taken public several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore.

Chief Executive Officer Carolyn Cross says: "We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare."

Cross said the fact that many hospitals were recommending Steriwave to other hospitals was "particularly encouraging".

"We believe this momentum will continue to increase, and commercial sales will become more significant in 2024."

Efforts to be a commercial success

currently achieving break-even or better

in my view but do you own research

Mark my words

dyor - imo

Chief Executive Officer Carolyn Cross commented: "It is hugely satisfying that Steriwave is now available in hospitals from coast to coast across Canada, giving patients enhanced protection against post-surgical infections. This new hospital deployment demonstrates Steriwave's growing status as an effective alternative to topical antibiotics for infection prevention that easily fits into existing hospital workflows."

4.10-4.359

Public opinion

Light fuse and stand well back - because this is taking off in 2024

and the sky is the only limitation

RBC target is 60p (will outperform the market)

imho dyo

Chief Executive Carolyn Cross says: "We have put great efforts into improving our commercial activity sales process, which has increased the speed of the average sales cycle from contact to deployment by 50%. We have appointed distributors in the UK, Spain, and Mexico and are gaining real momentum. What is particularly encouraging is that many hospitals are recommending Steriwave to other hospitals. We believe this momentum will continue to increase, and commercial sales will become more significant in 2024."

Am in total agreement with Rocket

Ondine met its 2023 target and more than doubled the number of hospitals using its groundbreaking photodisinfection technology to reduce healthcare-associated infections (HAIs)

· According to the NIH, HAIs affect more than 2 million patients a year in the US, leading to over 90,000 deaths and incurring costs exceeding $30 billion a year.[1]

Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. (AIM: OBI) will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens - bacteria, viruses and fungi - without causing antimicrobial resistance.

The Company has confirmed that it has more than doubled the number of Steriwave® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global emphasis on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine's photodisinfection technology.

The deployments are in areas of major surgery, including spinal, orthopedic, and cardiovascular. The antibiotic mupirocin has been used for nasal decolonization for the prevention of HAIs since the 1980s. However, mupirocin has resistance rates of up to 81%,[2] and very poor compliance.[3]

Successful C$4.91 raise supports ongoing commercialisation

Pentwater employs a bottom-up, opportunistic investment approach with a focus on event driven investing across the capital structure. Active risk management and capital preservation are key priorities. The seasoned Pentwater team enjoys a collaborative culture across the firm’s offices and strategies. In addition to our investment process, we are committed to providing investors with institutional quality client service, operations, and compliance.

Notification of major holdings

Https://www.pwcm.com/

Ondine Biomedical Inc - Vancouver-based life sciences company - Says it has raised GBP2.9 million via a placing. Says it will issue a further 1.1 million new shares at 9 pence each, representing a 9% premium to the closing price at November 29. Says it will use the proceeds to support its commercialisation in Canada, the UK, Spain and Mexico, and will provide a cash runway until at least the middle of the second quarter in 2024.

Https://www.britishbulls.com/SignalPage.aspx?lang=en&Ticker=obi.L

9.65-10.29

waiting on exciting new results

Analyst says 60p target

inho dyor